Skip to main content
. 2022 Jun 30;14(13):3203. doi: 10.3390/cancers14133203

Table 1.

Molecular structure, mechanisms of action and efficacy of new drugs tested in GBM in vitro or in vivo.

Name Structure Molecular Formula Mechanism Overall Survival (OS) References
Tamoxifen graphic file with name cancers-14-03203-i001.jpg C29H35NO2 OHT causes GBM cell death via an autophagy-related mechanism. 17.5 months [178,179]
Agathisflavone graphic file with name cancers-14-03203-i002.jpg C30H18O10 The drug decreased microglia neuroinflammation and reduced microglia and neuron neurotoxicity. Not tested in humans [176]
Mifepristone graphic file with name cancers-14-03203-i003.jpg C29H29NO The drug binds to progesterone and to glucocorticoids receptors. Resulting in a reduction of progesterone-dependent genes. Not tested in humans [169]
Metformin graphic file with name cancers-14-03203-i004.jpg C4H11N5 The drug down-regulates SOX2 expression in vitro, reduces the formation ability of glioblastoma cells, and blocks GBM xenograft growth in vivo. Not prolong OS [176,177]
Ko143 graphic file with name cancers-14-03203-i005.jpg C26H35N3O5 The drug could improve TMZ efficacy and may be a great inhibitor for P-glycoprotein. Not tested in humans [182,183]